Abraham Ceesay, Rapport Therapeutics CEO

Rap­port, a clin­i­cal-stage neu­ro­science biotech, files for IPO

Rap­port Ther­a­peu­tics, which emerged out of John­son & John­son’s neu­ro­science unit last year, has sub­mit­ted its pitch for a Nas­daq list­ing.

The Boston-based start­up plans …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.